Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.


Our approach is embodied in our pipeline of potential therapies that precisely target the root cause of disease to deliver transformational clinical benefits and the potential to change treatment expectations.
Our leadership team has deep experience developing drug candidates into leading medicines that make a meaningful difference in patients’ lives.



We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients with life-threatening diseases.


New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis

Data presented for the first time today during late-breaking oral session at the American Thoracic Society 2024 International Conference Patients who received ENV-101 experienced statistically significant improvements in lung function and total lung capacity, and reversal of multiple key quantitative measures of lung fibrosis through 12 weeks of treatment Findings reinforce potential...

Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference

Data from Phase 2a trial of novel Hedgehog (Hh) signaling pathway inhibitor in patients with idiopathic pulmonary fibrosis selected for featured late-breaking oral presentation on May 19 SAN DIEGO – May 1, 2024 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical...

Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines

– Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis, and ENV-501, a next-generation HER3-targeted antibody-drug conjugate, for solid tumors –  – Oversubscribed crossover financing from large, top-tier life sciences investor syndicate led by AyurMaya, an affiliate of Matrix Capital Management –  –...

Purple Lungs Image

Fibrotic Lung Disease

ENV-101 has the potential to be the first-ever disease-modifying therapy for pulmonary fibrosis, including IPF and PPF.

Blue Brain Diagram


ENV-501 is an optimized next-generation anti-HER3 antibody-drug conjugate with the potential to treat multiple tumor types.

Transforming Treatment Expectations

At Endeavor BioMedicines, we’re striving to develop groundbreaking medicines that go beyond slowing disease progression to reverse the trajectory of relentless diseases.